FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384156969> ?p ?o ?g. }

• W4384156969 endingPage "181" @default.
• W4384156969 startingPage "181" @default.
• W4384156969 abstract "The IMmotion010 trial, by Sumanta K Pal and colleagues,1Pal SK Uzzo R Karam JA et al.Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.Lancet. 2022; 400: 1103-1116Summary Full Text Full Text PDF PubMed Google Scholar showed that adjuvant atezolizumab is not superior to placebo in patients with kidney cancer who are at high risk of progression after surgery. Although the trial did not meet its primary endpoint, we applaud the authors for publishing the results of this phase 3 study2Bex A Uzzo R Karam JA et al.LBA66—IMmotion010: efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection.Ann Oncol. 2022; 33: S808-S869Google Scholar immediately after its presentation at the European Society of Medical Oncology congress. In the past, the lack of significant results has been associated with a delay in publishing full results of clinical trials.3Krzyzanowska MK Pintilie M Tannock IF Factors associated with failure to publish large randomized trials presented at an oncology meeting.JAMA. 2003; 290: 495-501Crossref PubMed Scopus (272) Google Scholar However, the publication of well designed negative trials has a tremendous impact in generating new scientific hypotheses and observations and, thus, should be encouraged.4Unger JM Barlow WE Ramsey SD LeBlanc M Blanke CD Hershman DL The scientific impact of positive and negative phase 3 cancer clinical trials.JAMA Oncol. 2016; 2: 875-881Crossref PubMed Scopus (36) Google Scholar Eligible patients for IMmotion010 required pathologically confirmed kidney cancer with either clear cell histology or sarcomatoid differentiation (regardless of the primary epithelial subtype). Among patients’ baseline characteristics, 7% in the atezolizumab-treated group and 8% in the observation group had non-clear cell kidney cancer (with sarcomatoid differentiation), including papillary, chromophobe, and other subtypes.1Pal SK Uzzo R Karam JA et al.Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.Lancet. 2022; 400: 1103-1116Summary Full Text Full Text PDF PubMed Google Scholar Inclusion of rare histologies in these large, randomised studies is extremely valuable, as doing a trial specifically for these rare tumours is fraught with difficulties. Since the biology of these rare tumours differs from the biology of clear cell histology, rare tumours should be considered as a separate exploratory statistical cohort.5Agrawal S Haas NB Bagheri M et al.Eligibility and radiologic assessment for adjuvant clinical trials in kidney cancer.JAMA Oncol. 2020; 6: 133-141Crossref PubMed Scopus (5) Google Scholar Although the numbers are small, reporting the survival outcomes for patients by rare histology, with or without therapy, would substantially contribute to our understanding of the natural history of these rare, high-risk tumours in the adjuvant setting. We declare no competing interests. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trialAtezolizumab as adjuvant therapy after resection for patients with renal cell carcinoma with increased risk of recurrence showed no evidence of improved clinical outcomes versus placebo. These study results do not support adjuvant atezolizumab for treatment of renal cell carcinoma. Full-Text PDF The value of IMmotion010 for rare kidney cancer histologies – Authors' replyWe appreciate the thoughtful insights from Giovanni M Iannantuono and colleagues on our Article1 and concur with the importance of addressing patients with renal cell carcinoma (RCC) bearing non-clear cell histology in prospective trials. The histological and molecular heterogeneity of non-clear cell RCC is underscored by the continued expansion of WHO's classification of renal tumours, which continues to evolve from traditionally defined entities based on tumour morphology and immunohistochemistry to a hybrid system that recognises the importance of genotype variations in biological behaviour. Full-Text PDF" @default.
• W4384156969 created "2023-07-14" @default.
• W4384156969 creator A5023616126 @default.
• W4384156969 creator A5039083730 @default.
• W4384156969 creator A5071716020 @default.
• W4384156969 date "2023-07-01" @default.
• W4384156969 modified "2023-09-30" @default.
• W4384156969 title "The value of IMmotion010 for rare kidney cancer histologies" @default.
• W4384156969 cites W2065347109 @default.
• W4384156969 cites W2296582581 @default.
• W4384156969 cites W2990024647 @default.
• W4384156969 cites W4295752424 @default.
• W4384156969 doi "https://doi.org/10.1016/s0140-6736(23)01067-x" @default.
• W4384156969 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37453746" @default.
• W4384156969 hasPublicationYear "2023" @default.
• W4384156969 type Work @default.
• W4384156969 citedByCount "0" @default.
• W4384156969 crossrefType "journal-article" @default.
• W4384156969 hasAuthorship W4384156969A5023616126 @default.
• W4384156969 hasAuthorship W4384156969A5039083730 @default.
• W4384156969 hasAuthorship W4384156969A5071716020 @default.
• W4384156969 hasBestOaLocation W43841569691 @default.
• W4384156969 hasConcept C121608353 @default.
• W4384156969 hasConcept C126322002 @default.
• W4384156969 hasConcept C141071460 @default.
• W4384156969 hasConcept C142724271 @default.
• W4384156969 hasConcept C143998085 @default.
• W4384156969 hasConcept C203092338 @default.
• W4384156969 hasConcept C204787440 @default.
• W4384156969 hasConcept C27081682 @default.
• W4384156969 hasConcept C2775949291 @default.
• W4384156969 hasConcept C2777472916 @default.
• W4384156969 hasConcept C2777701055 @default.
• W4384156969 hasConcept C2777863537 @default.
• W4384156969 hasConcept C2777982462 @default.
• W4384156969 hasConcept C2780057760 @default.
• W4384156969 hasConcept C2781068499 @default.
• W4384156969 hasConcept C535046627 @default.
• W4384156969 hasConcept C71924100 @default.
• W4384156969 hasConceptScore W4384156969C121608353 @default.
• W4384156969 hasConceptScore W4384156969C126322002 @default.
• W4384156969 hasConceptScore W4384156969C141071460 @default.
• W4384156969 hasConceptScore W4384156969C142724271 @default.
• W4384156969 hasConceptScore W4384156969C143998085 @default.
• W4384156969 hasConceptScore W4384156969C203092338 @default.
• W4384156969 hasConceptScore W4384156969C204787440 @default.
• W4384156969 hasConceptScore W4384156969C27081682 @default.
• W4384156969 hasConceptScore W4384156969C2775949291 @default.
• W4384156969 hasConceptScore W4384156969C2777472916 @default.
• W4384156969 hasConceptScore W4384156969C2777701055 @default.
• W4384156969 hasConceptScore W4384156969C2777863537 @default.
• W4384156969 hasConceptScore W4384156969C2777982462 @default.
• W4384156969 hasConceptScore W4384156969C2780057760 @default.
• W4384156969 hasConceptScore W4384156969C2781068499 @default.
• W4384156969 hasConceptScore W4384156969C535046627 @default.
• W4384156969 hasConceptScore W4384156969C71924100 @default.
• W4384156969 hasIssue "10397" @default.
• W4384156969 hasLocation W43841569691 @default.
• W4384156969 hasLocation W43841569692 @default.
• W4384156969 hasOpenAccess W4384156969 @default.
• W4384156969 hasPrimaryLocation W43841569691 @default.
• W4384156969 hasRelatedWork W1966781799 @default.
• W4384156969 hasRelatedWork W2135782240 @default.
• W4384156969 hasRelatedWork W2591501909 @default.
• W4384156969 hasRelatedWork W2757591860 @default.
• W4384156969 hasRelatedWork W2768139119 @default.
• W4384156969 hasRelatedWork W2803080661 @default.
• W4384156969 hasRelatedWork W2952305731 @default.
• W4384156969 hasRelatedWork W4298001713 @default.
• W4384156969 hasRelatedWork W4313543621 @default.
• W4384156969 hasRelatedWork W2940700619 @default.
• W4384156969 hasVolume "402" @default.
• W4384156969 isParatext "false" @default.
• W4384156969 isRetracted "false" @default.
• W4384156969 workType "article" @default.